Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
NCT05792462Phase 1Active, not recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Apr 2023
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of baricitinib in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Number of relapses at 96 weeks. Started Apr 2023; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05792462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05792462.